Contact
searchSearch
HMP Global
Login

Cholangiocarcinoma

Cholangiocarcinoma
Specialty Channel
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
Tanios Bekaii-Saab, MD
Videos
Pemigatinib Improves Outcomes Compared With Chemotherapy in FGFR2-Rearranged Cholangiocarcinoma
06/18/2026
Tanios Bekaii-Saab, MD, FACP
Tanios Bekaii-Saab, MD, discusses results from the phase 3 FIGHT-302 study which showed that first-line pemigatinib significantly improved progression-free survival, objective response rate, and duration of response compared with...
Tanios Bekaii-Saab, MD, discusses results from the phase 3 FIGHT-302 study which showed that first-line pemigatinib significantly improved progression-free survival, objective response rate, and duration of response compared with...
Tanios Bekaii-Saab, MD,...
06/18/2026
Oncology
Ghassan Abou-Alfa, MD
Videos
Infigratinib in Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
05/19/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses results from the phase 3 PROOF 301 trial evaluating infigratinib in patients with FGFR2 fusion-positive cholangiocarcinoma.
Ghassan Abou-Alfa, MD, discusses results from the phase 3 PROOF 301 trial evaluating infigratinib in patients with FGFR2 fusion-positive cholangiocarcinoma.
Ghassan Abou-Alfa, MD, discusses...
05/19/2026
Oncology
Alison Scram, MD
Videos
Zenocutuzumab for NRG1-Positive Cholangiocarcinoma
05/19/2026
Alison Schram, MD
Alison Schram, MD, discusses results from the phase 2 eNRGy trial which led to the recent FDA approval of zenocutuzumab for patients with NRG1-fusion positive cholangiocarcinoma.
Alison Schram, MD, discusses results from the phase 2 eNRGy trial which led to the recent FDA approval of zenocutuzumab for patients with NRG1-fusion positive cholangiocarcinoma.
Alison Schram, MD, discusses...
05/19/2026
Oncology
FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Neoadjuvant GOLP Demonstrates Efficacy, Safety in High-Risk Intrahepatic Cholangiocarcinoma
04/06/2026
Stephanie Holland
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial...
04/06/2026
Oncology
News
Tinengotinib Demonstrates Strong Antitumor Activity in FGFR-Altered Cholangiocarcinoma
02/04/2026
Stephanie Holland
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial...
02/04/2026
Oncology
News
Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
01/13/2026
Stephanie Holland
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2...
01/13/2026
Oncology
Conference Coverage
Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma
05/28/2024
Allison Casey
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial...
05/28/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
01/20/2024
Stephanie Holland
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study...
01/20/2024
Oncology

News

News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Neoadjuvant GOLP Demonstrates Efficacy, Safety in High-Risk Intrahepatic Cholangiocarcinoma
04/06/2026
Stephanie Holland
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial...
04/06/2026
Oncology
News
Tinengotinib Demonstrates Strong Antitumor Activity in FGFR-Altered Cholangiocarcinoma
02/04/2026
Stephanie Holland
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial...
02/04/2026
Oncology
News
Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
01/13/2026
Stephanie Holland
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2...
01/13/2026
Oncology
Conference Coverage
Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma
05/28/2024
Allison Casey
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial...
05/28/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
01/20/2024
Stephanie Holland
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study...
01/20/2024
Oncology
Conference Coverage
Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma
01/19/2024
Allison Casey
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a...
01/19/2024
Oncology
Conference Coverage
Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer
01/19/2024
Janelle Bradley
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology

Quiz
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma With Extrahepatic Metastases
11/27/2023
Do you know which outcome was less frequent among patients with cholangiocarcinoma with extrahepatic metastases who received liver-directed radiotherapy? Take our quick quiz to find out!
Do you know which outcome was less frequent among patients with cholangiocarcinoma with extrahepatic metastases who received liver-directed radiotherapy? Take our quick quiz to find out!
Do you know which outcome was...
11/27/2023
Oncology
Quiz
Adjuvant or Neoadjuvant Chemotherapy for Non-Metastatic Cholangiocarcinoma
06/15/2023
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with...
06/15/2023
Oncology
Quiz
Cholangioscopy for Diagnosis of Cholangiocarcinoma
06/15/2023
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose...
06/15/2023
Oncology
Quiz
Incidence of IDH Mutations in Cholangiocarcinoma
05/09/2023
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients...
05/09/2023
Oncology
Quiz
Quiz: IDH Mutations in Biliary Tract Cancers
04/11/2023
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract...
04/11/2023
Oncology
Quiz
Quiz: Outcomes of Liver Transplant vs Resection for Perihilar Cholangiocarcinoma
12/01/2022
How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...
How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...
How did the outcomes of patients...
12/01/2022
Oncology
Quiz
Quiz: Trastuzumab Biosimilar Plus FOLFOX for HER2-Positive Biliary Tract Cancer
11/30/2022
What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?
What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?
What was the approximate...
11/30/2022
Oncology
Quiz
Quiz: In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with intrahepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
11/02/2022
In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
In the phase 2 FIDES-01 study,...
11/02/2022
Oncology
Test Your Knowledge
Quiz: What Test Can Be Used to Compare OS, DFS in ICC?
02/24/2022
Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?
Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?
Which test can be used to...
02/24/2022
Oncology
Quiz
Quiz: Which Clinical Trial Was the Basis for Pemagatinib Approval?
02/14/2022
The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.
The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.
The FDA’s approval of...
02/14/2022
Oncology

Recent News

News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Neoadjuvant GOLP Demonstrates Efficacy, Safety in High-Risk Intrahepatic Cholangiocarcinoma
04/06/2026
Stephanie Holland
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial...
04/06/2026
Oncology
News
Tinengotinib Demonstrates Strong Antitumor Activity in FGFR-Altered Cholangiocarcinoma
02/04/2026
Stephanie Holland
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial...
02/04/2026
Oncology
News
Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
01/13/2026
Stephanie Holland
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2...
01/13/2026
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer
11/02/2023
Allison Casey
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA...
11/02/2023
Oncology
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
07/20/2023
Allison Casey
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab...
07/20/2023
Oncology
News
Annual MRI for Patients With Primary Sclerosing Cholangitis Failed to Provide Long-Term Cholangiocarcinoma Survival Benefit
11/21/2022
Allison Casey
Among patients with primary sclerosing cholangitis, yearly surveillance by MRI was not able to detect cholangiocarcinoma early enough to convey a long-term survival benefit.
Among patients with primary sclerosing cholangitis, yearly surveillance by MRI was not able to detect cholangiocarcinoma early enough to convey a long-term survival benefit.
Among patients with primary...
11/21/2022
Oncology
News
Trastuzumab Biosimilar Plus FOLFOX Shows Promise for HER2-Positive Biliary Tract Cancers
11/10/2022
In a phase 2 trial, trastuzumab biosimilar plus FOLFOX demonstrated promising activity and acceptable safety among patients with HER2-positive biliary tract cancers that had progressed on gemcitabine and cisplatin chemotherapy regimens.
In a phase 2 trial, trastuzumab biosimilar plus FOLFOX demonstrated promising activity and acceptable safety among patients with HER2-positive biliary tract cancers that had progressed on gemcitabine and cisplatin chemotherapy regimens.
In a phase 2 trial, trastuzumab...
11/10/2022
Oncology
News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use